Literature DB >> 23759464

Reduction of crime in first-onset psychosis: a secondary analysis of the OPUS randomized trial.

Hanne Stevens1, Esben Agerbo, Kimberlie Dean, Preben B Mortensen, Merete Nordentoft.   

Abstract

OBJECTIVE: Violence and criminality are adverse outcomes for some persons who develop psychotic illnesses. The extent to which treatment can reduce offending has rarely been studied. The aim of this study was to evaluate whether assertive specialized treatment would reduce the rate of crime in patients with a first episode of psychotic illness.
METHOD: From January 1998 to December 2000, a total of 547 patients aged 18-45 years with a first episode of schizophrenia spectrum disorder (ICD-10 diagnostic code within F2) were randomized to assertive specialized treatment or standard treatment in an outpatient setting. In the current secondary analysis of the data, levels of criminality during the 2-year treatment period and the 3 years following were assessed using official records from Danish registers. Main outcome measures were any offending and violent offending.
RESULTS: No significant reduction in violent offending or any offending was found in the assertive specialized treatment group (adjusted hazard ratio = 1.06; 95% CI, 0.72-1.56) compared with the control group. Prevalence of offending was low and had often commenced prior to inclusion in the trial.
CONCLUSIONS: While assertive specialized treatment has shown good treatment effects, it had no impact on rates of offending, thereby calling into question the potential efficacy of universally applied improvements in outpatient services with respect to reducing crime and violence. More specific interventions that address criminogenic needs in a more narrowly defined group of high-risk patients may be considered. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23759464     DOI: 10.4088/JCP.12m08156

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

1.  Clozapine Treatment and Offending: A Within-Subject Study of Patients With Psychotic Disorders in Sweden.

Authors:  Vishal Bhavsar; Kyriaki Kosidou; Linnea Widman; Nicola Orsini; John Hodsoll; Christina Dalman; James H MacCabe
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

Review 2.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Hanna Bergman; Mariam A Khokhar; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2017-01-06

3.  Analysis of Early Intervention Services on Adult Judicial Outcomes.

Authors:  Jessica M Pollard; Maria Ferrara; I-Hsin Lin; Suat Kucukgoncu; Tobias Wasser; Fangyong Li; Vinod H Srihari
Journal:  JAMA Psychiatry       Date:  2020-08-01       Impact factor: 21.596

4.  Interventions for prodromal stage of psychosis.

Authors:  Dina Bosnjak Kuharic; Ivana Kekin; Joanne Hew; Martina Rojnic Kuzman; Livia Puljak
Journal:  Cochrane Database Syst Rev       Date:  2019-11-01

5.  Specialised early intervention teams for recent-onset psychosis.

Authors:  Stephen Puntis; Amedeo Minichino; Franco De Crescenzo; Andrea Cipriani; Belinda Lennox; Rachael Harrison
Journal:  Cochrane Database Syst Rev       Date:  2020-11-02

6.  Specialised early intervention teams (extended time) for recent-onset psychosis.

Authors:  Stephen Puntis; Amedeo Minichino; Franco De Crescenzo; Andrea Cipriani; Belinda Lennox; Rachael Harrison
Journal:  Cochrane Database Syst Rev       Date:  2020-11-02

Review 7.  Could Expanding and Investing in First-Episode Psychosis Services Prevent Aggressive Behaviour and Violent Crime?

Authors:  Sheilagh Hodgins
Journal:  Front Psychiatry       Date:  2022-02-15       Impact factor: 4.157

8.  The Link Between Cannabis Use and Violent Behavior in the Early Phase of Psychosis: The Potential Role of Impulsivity.

Authors:  Valerie Moulin; David Framorando; Jacques Gasser; Elise Dan-Glauser
Journal:  Front Psychiatry       Date:  2022-03-22       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.